Switch theme
Sign up to access all valuation multiples
Third Harmonic Bio Inc is a biopharmaceutical company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company’s product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Its other product candidate THB335, is a potent, selective, oral small molecule KIT inhibitor, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway, and gastrointestinal tract.
2019
53
LTM Revenue n/a
LTM EBITDA -$51.3M
-$52.3M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Third Harmonic Bio has a last 12-month revenue of n/a and a last 12-month EBITDA of -$51.3M.
In the most recent fiscal year, Third Harmonic Bio achieved revenue of n/a and an EBITDA of -$58.8M.
Third Harmonic Bio expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Third Harmonic Bio valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$43.9M | -$58.8M | XXX | XXX | XXX |
| EBITDA Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
| Net Profit | -$35.2M | -$30.8M | XXX | XXX | XXX |
| Net Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Third Harmonic Bio's stock price is $5.
Third Harmonic Bio has current market cap of $230M, and EV of -$52.3M.
See Third Harmonic Bio trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$52.3M | $230M | XXX | XXX | XXX | XXX | $-1.06 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Third Harmonic Bio has market cap of $230M and EV of -$52.3M.
Third Harmonic Bio's trades at n/a LTM EV/Revenue multiple, and 1.0x LTM EBITDA.
Analysts estimate Third Harmonic Bio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Third Harmonic Bio and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | -$52.3M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | 0.9x | XXX | XXX | XXX |
| P/E | -5.0x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 1.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpThird Harmonic Bio's NTM/LTM revenue growth is n/a
Third Harmonic Bio's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $1.1M for the same period.
Over next 12 months, Third Harmonic Bio's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Third Harmonic Bio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Third Harmonic Bio and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | 34% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Third Harmonic Bio acquired XXX companies to date.
Last acquisition by Third Harmonic Bio was XXXXXXXX, XXXXX XXXXX XXXXXX . Third Harmonic Bio acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Third Harmonic Bio founded? | Third Harmonic Bio was founded in 2019. |
| Where is Third Harmonic Bio headquartered? | Third Harmonic Bio is headquartered in United States of America. |
| How many employees does Third Harmonic Bio have? | As of today, Third Harmonic Bio has 53 employees. |
| Who is the CEO of Third Harmonic Bio? | Third Harmonic Bio's CEO is Ms. Natalie C. Holles. |
| Is Third Harmonic Bio publicy listed? | Yes, Third Harmonic Bio is a public company listed on NAS. |
| What is the stock symbol of Third Harmonic Bio? | Third Harmonic Bio trades under THRD ticker. |
| When did Third Harmonic Bio go public? | Third Harmonic Bio went public in 2022. |
| Who are competitors of Third Harmonic Bio? | Similar companies to Third Harmonic Bio include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Third Harmonic Bio? | Third Harmonic Bio's current market cap is $230M |
| What is the current EBITDA of Third Harmonic Bio? | Third Harmonic Bio's last 12-month EBITDA is -$51.3M. |
| What is the current EV/EBITDA multiple of Third Harmonic Bio? | Current EBITDA multiple of Third Harmonic Bio is 1.0x. |
| Is Third Harmonic Bio profitable? | Yes, Third Harmonic Bio is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
